A retrospective study aseessing the efficacy of Elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat fixed dose combination in virologically suppressed HIV-1 infected adults with or without the archived NRTI resistance mutation M184V/I

Trial Profile

A retrospective study aseessing the efficacy of Elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat fixed dose combination in virologically suppressed HIV-1 infected adults with or without the archived NRTI resistance mutation M184V/I

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2016

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top